Compare MRTN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | NVCR |
|---|---|---|
| Founded | 1946 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2015 |
| Metric | MRTN | NVCR |
|---|---|---|
| Price | $14.69 | $15.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 843.9K | ★ 1.5M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,131,455,000.00 | $655,353,000.00 |
| Revenue This Year | $2.23 | $7.72 |
| Revenue Next Year | $8.59 | $6.74 |
| P/E Ratio | $69.14 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $9.35 | $9.82 |
| 52 Week High | $15.31 | $20.05 |
| Indicator | MRTN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 67.83 |
| Support Level | $14.20 | $12.66 |
| Resistance Level | $15.31 | N/A |
| Average True Range (ATR) | 0.47 | 0.79 |
| MACD | -0.06 | 0.50 |
| Stochastic Oscillator | 56.64 | 77.54 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.